title: The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
abstract: BACKGROUND
  The efficacy of antipsychotics can be evaluated using the dimensional models of schizophrenic symptoms. The D2/D3-selective antagonist amisulpride has shown similar efficacy and tolerability to other atypical antipsychotics. The aim of the present study was to determine the efficacy of amisulpride on the dimensional model of schizophrenic symptoms and tolerability in latin schizophrenic patients.
  
  
  METHODS
  Eighty schizophrenic patients were enrolled and 70 completed a prospective open-label 3-month study with amisulpride. The schizophrenic symptoms, psychosocial functioning and side-effects were evaluated with standardized scales.
  
  
  RESULTS
  The patients showed significant improvement in the five dimensions evaluated. Amisulpride (median final dose 357.1 mg/d) was well-tolerated without treatment-emergent extrapyramidal side-effects.
  
  
  CONCLUSIONS
  Amisulpride showed efficacy on different psychopathological dimensions and was well tolerated, leading to consider this drug a first line choice for the treatment of schizophrenia.
authors.affiliation: Psychiatry Department, National Institute of Neurology and Neurosurgery, Mexico City, Mexico. Mdmiguelherrera@aol.com
authors.forename: Miguel
authors.initials: M
authors.lastname: Herrera-Estrella
authors.forename: Rogelio
authors.initials: R
authors.lastname: Apiquian
authors.forename: Ana
authors.initials: A
authors.lastname: Fresan
authors.forename: Isabel
authors.initials: I
authors.lastname: Sanchez-Torres
mesh_terms: D000328:Adult; D000077582:Amisulpride; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008960:Models, Psychological; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013469:Sulpiride / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D013469:Sulpiride; D000077582:Amisulpride